The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
MAVERICC: A randomized phase II study of mFOLFOX6-bevacizumab (BV) versus FOLFIRI-BV with prospective biomarker stratification in previously untreated metastatic colorectal cancer (mCRC).
Sachdev P. Thomas
No relevant relationships to disclose
Suprith Badarinath
No relevant relationships to disclose
Richard H. Greenberg
No relevant relationships to disclose
Sang Y. Huh
No relevant relationships to disclose
Kulumani M Sivarajan
Research Funding - Genentech
Shibao Feng
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Stefan Scherer
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Christine Litz Curry
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Christiane Langer
Employment or Leadership Position - Roche/Genentech
Stock Ownership - Roche
Heinz-Josef Lenz
Consultant or Advisory Role - Genentech; Response Genetics
Stock Ownership - Response Genetics
Honoraria - Genentech
Research Funding - Genentech